Revised forecast
Fiscal year ending September 2026 · Second quarter (interim period) and full yearPrevious forecast published 7 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
For the second quarter (interim period), revenue, operating income and ordinary income are expected to substantially exceed the previous forecasts, mainly because numerous projects involving the core MI・RA・Is product series, for which revenue had been scheduled from the third quarter onward, went into operation ahead of schedule. Although an impairment loss related to the new Doctor Connect business is expected to be recorded as an extraordinary loss, interim net income is also expected to exceed the previous forecast. For the full year, the forecasts for revenue, operating income and ordinary income have been revised upward, primarily reflecting the factors behind the interim-period revisions, while the forecast for net income has been left unchanged due to the recognition of the impairment loss.
Details Impairment loss related to the new smartphone service business, Doctor Connect / Amount Not disclosed
| Item | Details |
|---|---|
| Net Sales | Second quarter (interim period) 9,200 / Full year 15,000 → Second quarter (interim period) 10,700 / Full year 16,000（Second quarter (interim period) 16.3 / Full year 6.7） |
| Operating profit | Second quarter (interim period) 1,020 / Full year 1,500 → Second quarter (interim period) 1,380 / Full year 1,600（Second quarter (interim period) 35.3 / Full year 6.7） |
| Ordinary income | Second quarter (interim period) 1,020 / Full year 1,500 → Second quarter (interim period) 1,380 / Full year 1,600（Second quarter (interim period) 35.3 / Full year 6.7） |
| Profit attributable to owners of the parent | Second quarter (interim period) 620 / Full year 870 → Second quarter (interim period) 690 / Full year 870（Second quarter (interim period) 11.3 / Full year Not disclosed） |
| Net income per share | Second quarter (interim period) 37.26 / Full year 52.28 → Second quarter (interim period) 41.43 / Full year 52.21 |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Second quarter (interim period) and full year |
| Publication date of previous forecast | 7 November 2025 |
| Previous-period results | Second quarter (interim period) Net Sales 9,199 / Operating profit 1,230 / Ordinary income 1,239 / Interim net income attributable to owners of the parent 707 / Interim net income per share 46.48 / Full year Net Sales 15,831 / Operating profit 1,411 / Ordinary income 1,426 / Profit attributable to owners of the parent 1,557 / Net income per share 98.85 |
| Reason for the revision | For the second quarter (interim period), revenue, operating income and ordinary income are expected to substantially exceed the previous forecasts, mainly because numerous projects involving the core MI・RA・Is product series, for which revenue had been scheduled from the third quarter onward, went into operation ahead of schedule. Although an impairment loss related to the new Doctor Connect business is expected to be recorded as an extraordinary loss, interim net income is also expected to exceed the previous forecast. For the full year, the forecasts for revenue, operating income and ordinary income have been revised upward, primarily reflecting the factors behind the interim-period revisions, while the forecast for net income has been left unchanged due to the recognition of the impairment loss. |
| Details and amount of extraordinary loss | Details Impairment loss related to the new smartphone service business, Doctor Connect / Amount Not disclosed |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Numerous projects involving the core MI・RA・Is product series, for which revenue had been scheduled from the third quarter onward, went into operation ahead of schedule. Although an impairment loss related to the new Doctor Connect business is expected to be recorded as an extraordinary loss, interim net income is expected to exceed the previous forecast, while full-year net income has been left unchanged due to the impact of the impairment loss.